Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients - worldwide battlefield

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F15%3A10293577" target="_blank" >RIV/00216208:11140/15:10293577 - isvavai.cz</a>

Alternative codes found

RIV/00669806:_____/15:10293577

Result on the web

<a href="http://dx.doi.org/10.4149/neo_2015_021" target="_blank" >http://dx.doi.org/10.4149/neo_2015_021</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4149/neo_2015_021" target="_blank" >10.4149/neo_2015_021</a>

Result language

angličtina

Original language name

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients - worldwide battlefield

Original language description

Advances in understanding the pathogenesis of chronic myeloid leukemia (CML) and implementation of the therapy with tyrosine kinase inhibitors (TKI) could be considered as a prototype of successful fight against cancer. However, for an optimally responding patient it is recommended to follow the TKI therapy indefinitely. The question about the possibility of safe TKI treatment discontinuation in certain clinical situations was raised and is currently under close investigation worldwide. Currently, imatinib discontinuation trails have shown that about 60% of eligible patients experienced molecular recurrence within 6 months of treatment discontinuation, while the remaining 40% remained in defined deep molecular response throughout the duration of mostlytwo years follow-up. Interestingly, retreatment with the same TKI or another TKI was successful in the vast majority of patients demonstrating molecular recurrence of the disease. These findings support the concept of safe TKI treatment

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/NT14227" target="_blank" >NT14227: Determining predictive factors for a therapeutic effect of chemotherapy in patients with stomach cancer</a><br>

Continuities

S - Specificky vyzkum na vysokych skolach

Publication year

2015

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Neoplasma

ISSN

0028-2685

e-ISSN

—

Volume of the periodical

62

Issue of the periodical within the volume

2

Country of publishing house

SK - SLOVAKIA

Number of pages

5

Pages from-to

167-171

UT code for WoS article

000362862400001

EID of the result in the Scopus database

2-s2.0-84943633434